{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:12:38Z","timestamp":1777554758030,"version":"3.51.4"},"reference-count":79,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:p>As treatment with immune checkpoint inhibitors (CPIs) for cancer increases, so has the incidence of immune-related cutaneous adverse events (irCAEs). These toxicities can significantly impact quality of life and may be dose-limiting. Current guidelines for irCAEs offer only corticosteroids or CPI discontinuation. Evidence supports biologic immunomodulatory therapies when corticosteroids fail or need avoidance. A review of literature from 2010 to 2020 yielded 45 articles, resulting in 185 irCAEs, including bullous pemphigoid\u2013like eruption (n = 55), psoriasis\/psoriasiform dermatitis (n = 41), and maculopapular rash (n = 31). Treatments included immunomodulators, intravenous immunoglobulin, aprepitant, acitretin, tetracyclines, and biologic agents. Overall, 92.3% of patients saw improvement or resolution of their rash. Bullous pemphigoid\u2013like eruptions were treated with a tetracycline +\/\u2212 niacinamide (94.7% success [18\/19]), omalizumab (100% success [7\/7]), and rituximab (100% success [10\/10]). Although prospective research is required, this review provides a comprehensive list of successful, non-corticosteroid treatment options for irCAEs to improve compliance with lifesaving cancer therapy.<\/jats:p>","DOI":"10.1097\/der.0000000000000776","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T08:34:42Z","timestamp":1629275682000},"page":"201-208","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Systemic Treatment of Cutaneous Adverse Events after Immune Checkpoint Inhibitor Therapy: A Review"],"prefix":"10.1177","volume":"34","author":[{"given":"Alexandria M.","family":"Brown","sequence":"first","affiliation":[{"name":"From the,  Baylor College of Medicine, School of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wylie","family":"Masterson","sequence":"additional","affiliation":[{"name":"McGovern Medical School, University of Texas Health Science Center at Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lo","sequence":"additional","affiliation":[{"name":"From the,  Baylor College of Medicine, School of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[{"name":"McGovern Medical School, University of Texas Health Science Center at Houston"},{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"issue":"2","key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry JL","year":"2017","unstructured":"Curry JL, , Tetzlaff MT, , Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol, 2017; 44(2):158\u2013176. doi:10.1111\/cup.12858.","journal-title":"J Cutan Pathol"},{"issue":"21","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber JS","year":"2012","unstructured":"Weber JS, , K\u00e4hler KC, , Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol Off J Am Soc Clin Oncol, 2012; 30(21):2691\u20132697. doi:10.1200\/JCO.2012.41.6750.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber JS","year":"2017","unstructured":"Weber JS, , Hodi FS, , Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol Off J Am Soc Clin Oncol, 2017; 35(7):785\u2013792. doi:10.1200\/JCO.2015.66.1389.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"issue":"6","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40257-018-0376-3","article-title":"Retrospective chart review of cutaneous adverse events associated with tremelimumab in 17 patients","volume":"19","author":"Welborn M","year":"2018","unstructured":"Welborn M, , Kubicki SL, , Garg N, et al. Retrospective chart review of cutaneous adverse events associated with tremelimumab in 17 patients. Am J Clin Dermatol, 2018; 19(6):899\u2013905. doi:10.1007\/s40257-018-0376-3.","journal-title":"Am J Clin Dermatol"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-02505-2_5"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"issue":"22","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non\u2013small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti B","year":"2019","unstructured":"Ricciuti B, , Dahlberg SE, , Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non\u2013small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol Off J Am Soc Clin Oncol, 2019; 37(22):1927\u20131934. doi:10.1200\/JCO.19.00189.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"issue":"1","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"e000477","DOI":"10.1136\/esmoopen-2018-000477","article-title":"Early use of steroids affects immune cells and impairs immunotherapy efficacy","volume":"4","author":"Della Corte CM","year":"2019","unstructured":"Della Corte CM, , Morgillo F. Early use of steroids affects immune cells and impairs immunotherapy efficacy. ESMO Open, 2019; 4(1):e000477. doi:10.1136\/esmoopen-2018-000477.","journal-title":"ESMO Open"},{"issue":"28","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour KC","year":"2018","unstructured":"Arbour KC, , Mezquita L, , Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol, 2018; 36(28):2872\u20132878. doi:10.1200\/JCO.2018.79.0006.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"28","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat TZ","year":"2015","unstructured":"Horvat TZ, , Adel NG, , Dang T-O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol Off J Am Soc Clin Oncol, 2015; 33(28):3193\u20133198. doi:10.1200\/JCO.2015.60.8448.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"e_1_3_1_16_2","first-page":"139","volume":"54","author":"Michot JM","year":"2016","unstructured":"Michot JM, , Bigenwald C, , Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer Oxf Engl 1990, 2016; 54:139\u2013148. doi:10.1016\/j.ejca.2015.11.016.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420943260"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"issue":"30","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips GS","year":"2019","unstructured":"Phillips GS, , Wu J, , Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol Off J Am Soc Clin Oncol, 2019; 37(30):2746\u20132758. doi:10.1200\/JCO.18.02141.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68101"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exphem.2016.10.005","article-title":"Tumor necrosis factor \u03b1 in the onset and progression of leukemia","volume":"45","author":"Zhou X","year":"2017","unstructured":"Zhou X, , Li Z, , Zhou J. Tumor necrosis factor \u03b1 in the onset and progression of leukemia. Exp Hematol, 2017; 45:17\u201326. doi:10.1016\/j.exphem.2016.10.005.","journal-title":"Exp Hematol"},{"issue":"20","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani K","year":"2017","unstructured":"Esfahani K, , Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med, 2017; 376(20):1989\u20131991. doi:10.1056\/NEJMc1703047.","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse W","year":"2012","unstructured":"Busse W, , Buhl R, , Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol, 2012; 129(4):983\u2013989.e6. doi:10.1016\/j.jaci.2012.01.033.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062"},{"issue":"11","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer","volume":"55","author":"Law-Ping-Man S","year":"2016","unstructured":"Law-Ping-Man S, , Martin A, , Briens E, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatol Oxf Engl, 2016; 55(11):2087\u20132089. doi:10.1093\/rheumatology\/kew281.","journal-title":"Rheumatol Oxf Engl"},{"issue":"3","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ajd.12488","article-title":"Late presentation of generalised bullous pemphigoid\u2013like reaction in a patient treated with pembrolizumab for metastatic melanoma","volume":"58","author":"Parakh S","year":"2017","unstructured":"Parakh S, , Nguyen R, , Opie JM, et al. Late presentation of generalised bullous pemphigoid\u2013like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas J Dermatol, 2017; 58(3):e109\u2013e112. doi:10.1111\/ajd.12488.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti\u2013PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen J","year":"2017","unstructured":"Bonigen J, , Raynaud-Donzel C, , Hureaux J, et al. Anti\u2013PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol JEADV, 2017; 31(5):e254\u2013e257. doi:10.1111\/jdv.14011.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"6","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky W","year":"2016","unstructured":"Damsky W, , Kole L, , Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep, 2016; 2(6):442\u2013444. doi:10.1016\/j.jdcr.2016.05.009.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe O","year":"2017","unstructured":"Rofe O, , Bar-Sela G, , Keidar Z, et al. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol, 2017; 42(3):309\u2013312. doi:10.1111\/ced.13042.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1111\/jdv.14179","article-title":"Two cases of anti\u2013programmed cell death 1\u2013associated bullous pemphigoid\u2013like disease and eruptive keratoacanthomas featuring combined histopathology","volume":"31","author":"Bandino JP","year":"2017","unstructured":"Bandino JP, , Perry DM, , Clarke CE, et al. Two cases of anti\u2013programmed cell death 1\u2013associated bullous pemphigoid\u2013like disease and eruptive keratoacanthomas featuring combined histopathology. J Eur Acad Dermatol Venereol JEADV, 2017; 31(8):e378\u2013e380. doi:10.1111\/jdv.14179.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"6","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby L","year":"2017","unstructured":"Sowerby L, , Dewan AK, , Granter S, et al. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol, 2017; 153(6):603\u2013605. doi:10.1001\/jamadermatol.2017.0091.","journal-title":"JAMA Dermatol"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito J","year":"2017","unstructured":"Ito J, , Fujimoto D, , Nakamura A, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer Amst Neth, 2017; 109:58\u201361. doi:10.1016\/j.lungcan.2017.04.020.","journal-title":"Lung Cancer Amst Neth"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.03.016"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13044"},{"issue":"6","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti\u2013PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri D","year":"2017","unstructured":"Voudouri D, , Nikolaou V, , Laschos K, et al. Anti\u2013PD1\/PDL1 induced psoriasis. Curr Probl Cancer, 2017; 41(6):407\u2013412. doi:10.1016\/j.currproblcancer.2017.10.003.","journal-title":"Curr Probl Cancer"},{"issue":"9","key":"e_1_3_1_38_2","doi-asserted-by":"crossref","DOI":"10.5070\/D3239036484","article-title":"Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab","volume":"23","author":"Sundaresan S","year":"2017","unstructured":"Sundaresan S, , Nguyen KT, , Nelson KC, et al. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab. Dermatol Online J, 2017; 23(9).","journal-title":"Dermatol Online J"},{"issue":"1","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000485910","article-title":"A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and\/or complementary immunomodulatory effects","volume":"10","author":"Utsunomiya A","year":"2018","unstructured":"Utsunomiya A, , Oyama N, , Iino S, et al. A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and\/or complementary immunomodulatory effects. Case Rep Dermatol, 2018; 10(1):1\u20136. doi:10.1159\/000485910.","journal-title":"Case Rep Dermatol"},{"issue":"11","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/ijd.13970","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid","volume":"57","author":"Ridpath AV","year":"2018","unstructured":"Ridpath AV, , Rzepka PV, , Shearer SM, et al. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid. Int J Dermatol, 2018; 57(11):1372\u20131374. doi:10.1111\/ijd.13970.","journal-title":"Int J Dermatol"},{"issue":"4","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug V","year":"2018","unstructured":"Haug V, , Behle V, , Benoit S, et al. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma. Br J Dermatol, 2018; 179(4):993\u2013994. doi:10.1111\/bjd.16780.","journal-title":"Br J Dermatol"},{"issue":"10","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez AT","year":"2018","unstructured":"Lopez AT, , Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist, 2018; 23(10):1119\u20131126. doi:10.1634\/theoncologist.2018-0128.","journal-title":"Oncologist"},{"issue":"6","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel J","year":"2018","unstructured":"Siegel J, , Totonchy M, , Damsky W, et al. Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol, 2018; 79(6):1081\u20131088. doi:10.1016\/j.jaad.2018.07.008.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2018.07.023","article-title":"Anti\u2013PD1 therapy\u2013associated cutaneous leucocytoclastic vasculitis: a case series","volume":"57","author":"Tomelleri A","year":"2018","unstructured":"Tomelleri A, , Campochiaro C, , De Luca G, et al. Anti\u2013PD1 therapy\u2013associated cutaneous leucocytoclastic vasculitis: a case series. Eur J Intern Med, 2018; 57:e11\u2013e12. doi:10.1016\/j.ejim.2018.07.023.","journal-title":"Eur J Intern Med"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti\u2013programmed death-1\/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu C","year":"2018","unstructured":"Zumelzu C, , Alexandre M, , Le Roux C, et al. Mucous membrane pemphigoid, bullous pemphigoid, and anti\u2013programmed death-1\/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature. Front Med, 2018; 5:268. doi:10.3389\/fmed.2018.00268.","journal-title":"Front Med"},{"key":"e_1_3_1_46_2","first-page":"97","article-title":"Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide","volume":"107","author":"Rios A","year":"2019","unstructured":"Rios A, , Cen P, , Dinh B, et al. Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide. Eur J Cancer Oxf Engl 1990, 2019; 107:97\u201399. doi:10.1016\/j.ejca.2018.11.025.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0481-0"},{"issue":"3","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1111\/ajd.12987","article-title":"Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect","volume":"60","author":"Grimaux X","year":"2019","unstructured":"Grimaux X, , Delva R, , Jadaud E, et al. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas J Dermatol, 2019; 60(3):e235\u2013e236. doi:10.1111\/ajd.12987.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1634\/theoncologist.2018-0531","article-title":"Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine","volume":"24","author":"Fixsen E","year":"2019","unstructured":"Fixsen E, , Patel J, , Selim MA, et al. Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine. Oncologist, 2019; 24(3):e103\u2013e105. doi:10.1634\/theoncologist.2018-0531.","journal-title":"Oncologist"},{"key":"e_1_3_1_50_2","first-page":"107","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast","volume":"110","author":"Fattore D","year":"2019","unstructured":"Fattore D, , Annunziata MC, , Panariello L, et al. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer Oxf Engl 1990, 2019; 110:107\u2013109. doi:10.1016\/j.ejca.2019.01.010.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0682"},{"issue":"9","key":"e_1_3_1_52_2","first-page":"359","article-title":"A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: brief communication","volume":"42","author":"Bezinelli LM","year":"2019","unstructured":"Bezinelli LM, , Eduardo FP, , Migliorati CA, et al. A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: brief communication. J Immunother Hagerstown Md 1997, 2019; 42(9):359\u2013362. doi:10.1097\/CJI.0000000000000280.","journal-title":"J Immunother Hagerstown Md 1997"},{"issue":"3","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature","volume":"30","author":"Kosche C","year":"2020","unstructured":"Kosche C, , Stout M, , Sosman J, et al. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. Melanoma Res, 2020; 30(3):313\u2013316. doi:10.1097\/CMR.0000000000000642.","journal-title":"Melanoma Res"},{"issue":"10","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jdcr.2019.07.015","article-title":"Nonbullous pemphigoid secondary to PD-1 inhibition","volume":"5","author":"Singer S","year":"2019","unstructured":"Singer S, , Nelson CA, , Lian CG, et al. Nonbullous pemphigoid secondary to PD-1 inhibition. JAAD Case Rep, 2019; 5(10):898\u2013903. doi:10.1016\/j.jdcr.2019.07.015.","journal-title":"JAAD Case Rep"},{"issue":"10","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","DOI":"10.5070\/D32510045817","article-title":"Bullous dermatoses secondary to anti\u2013PD-L1 agents: a case report and review of the literature","volume":"25","author":"Kosche C","year":"2019","unstructured":"Kosche C, , Owen JL, , Sadowsky LM, et al. Bullous dermatoses secondary to anti\u2013PD-L1 agents: a case report and review of the literature. Dermatol Online J, 2019; 25(10).","journal-title":"Dermatol Online J"},{"issue":"10","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","DOI":"10.5070\/D32510045821","article-title":"Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab","volume":"25","author":"Kosche C","year":"2019","unstructured":"Kosche C, , Owen JL, , Choi JN. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab. Dermatol Online J, 2019; 25(10).","journal-title":"Dermatol Online J"},{"issue":"10","key":"e_1_3_1_57_2","first-page":"e5824","article-title":"A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report","volume":"11","author":"Monsour EP","year":"2019","unstructured":"Monsour EP, , Pothen J, , Balaraman R. A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report. Cureus, 2019; 11(10):e5824. doi:10.7759\/cureus.5824.","journal-title":"Cureus"},{"key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fmed.2019.00262","article-title":"Recurrence of pemphigus vulgaris under nivolumab therapy","volume":"6","author":"Krammer S","year":"2019","unstructured":"Krammer S, , Krammer C, , Salzer S, et al. Recurrence of pemphigus vulgaris under nivolumab therapy. Front Med, 2019; 6:262. doi:10.3389\/fmed.2019.00262.","journal-title":"Front Med"},{"issue":"8","key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/cup.13687","article-title":"Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: a case series","volume":"47","author":"Morris LM","year":"2020","unstructured":"Morris LM, , Lewis HA, , Cornelius LA, et al. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: a case series. J Cutan Pathol, 2020; 47(8):742\u2013746. doi:10.1111\/cup.13687.","journal-title":"J Cutan Pathol"},{"issue":"4","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjd.19129","article-title":"Treatment of severe cutaneous adverse reaction with tocilizumab","volume":"183","author":"Hibler BP","year":"2020","unstructured":"Hibler BP, , Markova A. Treatment of severe cutaneous adverse reaction with tocilizumab. Br J Dermatol, 2020; 183(4):785\u2013787. doi:10.1111\/bjd.19129.","journal-title":"Br J Dermatol"},{"issue":"6","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.12788\/cutis.0011","article-title":"Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non\u2013small cell lung cancer","volume":"105","author":"Schwartzman G","year":"2020","unstructured":"Schwartzman G, , Simpson MM, , Jones R, et al. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non\u2013small cell lung cancer. Cutis, 2020; 105(6):E9\u2013E12.","journal-title":"Cutis"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946370"},{"issue":"2","key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation","volume":"46","author":"Bui AN","year":"2021","unstructured":"Bui AN, , Hirner J, , Singer SB, et al. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Clin Exp Dermatol, 2021; 46(2):328\u2013337. doi:10.1111\/ced.14449.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"e_1_3_1_64_2","doi-asserted-by":"crossref","DOI":"10.5070\/D3268049887","article-title":"Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature","volume":"26","author":"Messer A","year":"2020","unstructured":"Messer A, , Drozd B, , Glitza IC, et al. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Dermatol Online J, 2020; 26(8).","journal-title":"Dermatol Online J"},{"issue":"4","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang SJE","year":"2016","unstructured":"Hwang SJE, , Carlos G, , Chou S, et al. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res, 2016; 26(4):413\u2013416. doi:10.1097\/CMR.0000000000000260.","journal-title":"Melanoma Res"},{"issue":"3","key":"e_1_3_1_66_2","first-page":"149","article-title":"Toxic epidermal necrolysis\u2013like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar N","year":"2016","unstructured":"Nayar N, , Briscoe K, , Fernandez Penas P. Toxic epidermal necrolysis\u2013like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother Hagerstown Md 1997, 2016; 39(3):149\u2013152. doi:10.1097\/CJI.0000000000000112.","journal-title":"J Immunother Hagerstown Md 1997"},{"issue":"7","key":"e_1_3_1_67_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings H-E","year":"2015","unstructured":"Teulings H-E, , Limpens J, , Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol, 2015; 33(7):773\u2013781. doi:10.1200\/JCO.2014.57.4756.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2707"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2742"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-208249"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177360"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13984"},{"issue":"5","key":"e_1_3_1_74_2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2012.27","article-title":"Targeting CD20 in melanoma patients at high risk of disease recurrence","volume":"20","author":"Pinc A","year":"2012","unstructured":"Pinc A, , Somasundaram R, , Wagner C, et al. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther J Am Soc Gene Ther, 2012; 20(5):1056\u20131062. doi:10.1038\/mt.2012.27.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"2","key":"e_1_3_1_75_2","first-page":"104","article-title":"Breast cancer in patients of rheumatoid arthritis with methotrexate therapy mimicking histopathological changes after neoadjuvant chemotherapy","volume":"42","author":"Kumaki N","year":"2017","unstructured":"Kumaki N, , Okamatsu C, , Tokuda Y, et al. Breast cancer in patients of rheumatoid arthritis with methotrexate therapy mimicking histopathological changes after neoadjuvant chemotherapy. Tokai J Exp Clin Med, 2017; 42(2):104\u2013108.","journal-title":"Tokai J Exp Clin Med"},{"issue":"3","key":"e_1_3_1_76_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","article-title":"Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis","volume":"47","author":"Wessels J a M","year":"2008","unstructured":"Wessels J a M, , Huizinga TWJ, , H-J Guchelaar. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatol Oxf Engl, 2008; 47(3):249\u2013255. doi:10.1093\/rheumatology\/kem279.","journal-title":"Rheumatol Oxf Engl"},{"issue":"5","key":"e_1_3_1_77_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.biopha.2004.04.010","article-title":"Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them","volume":"58","author":"B\u00f6hm I","year":"2004","unstructured":"B\u00f6hm I. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother Biomedecine Pharmacother, 2004; 58(5):338\u2013343. doi:10.1016\/j.biopha.2004.04.010.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"issue":"10","key":"e_1_3_1_78_2","first-page":"667","article-title":"Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells","volume":"31","author":"Brody M","year":"1993","unstructured":"Brody M, , B\u00f6hm I, , Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem J Forum Eur Clin Chem Soc, 1993; 31(10):667\u2013674. doi:10.1515\/cclm.1993.31.10.667.","journal-title":"Eur J Clin Chem Clin Biochem J Forum Eur Clin Chem Soc"},{"issue":"1","key":"e_1_3_1_79_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review","volume":"310","author":"Saniklidou AH","year":"2018","unstructured":"Saniklidou AH, , Tighe PJ, , Fairclough LC, et al. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Arch Dermatol Res, 2018; 310(1):11\u201328. doi:10.1007\/s00403-017-1789-1.","journal-title":"Arch Dermatol Res"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0401-6"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1097\/DER.0000000000000776","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000776","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:06:44Z","timestamp":1777399604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6,1]]}},"alternative-id":["10.1097\/DER.0000000000000776"],"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000776","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]}}}